Innovative Findings on PB-223 ADC in Human Cancer Targeting Unveiled at SITC 2026#United_States#Phoenix#Precision_Biologics#PB-223#SITC_2026
Innovative Findings on PB-223 ADC in Human Cancer Targeting Unveiled at SITC 2026
Precision Biologics, Inc. presented encouraging findings on the PB-223 ADC targeting specific tumors at the SITC 2026, showcasing potential advancements in cancer treatment.
third-news.com
November 6, 2026 at 2:34 PM
Innovative Findings on PB-223 ADC in Human Cancer Targeting Unveiled at SITC 2026#United_States#Phoenix#Precision_Biologics#PB-223#SITC_2026
Precision Biologics Unveils Novel Acute Myeloid Leukemia Target at AACR 2026#USA#San_Diego#Acute_Myeloid_Leukemia#CAR-NK#Precision_Biologics
Precision Biologics Unveils Novel Acute Myeloid Leukemia Target at AACR 2026
Precision Biologics is set to reveal groundbreaking findings related to a new target for CAR-NK therapy in Acute Myeloid Leukemia at the AACR Annual Meeting.
third-news.com
April 17, 2026 at 1:29 PM
Precision Biologics Unveils Novel Acute Myeloid Leukemia Target at AACR 2026#USA#San_Diego#Acute_Myeloid_Leukemia#CAR-NK#Precision_Biologics
Precision Biologics to Present Novel Monoclonal Antibodies at Festival of Biologics USA#USA#San_Diego#Cancer_Treatment#Monoclonal_Antibodies#Precision_Biologics
Precision Biologics to Present Novel Monoclonal Antibodies at Festival of Biologics USA
Precision Biologics will showcase groundbreaking monoclonal antibodies targeting cancer-specific markers at the Festival of Biologics USA in San Diego.
third-news.com
March 2, 2026 at 2:59 PM
Precision Biologics to Present Novel Monoclonal Antibodies at Festival of Biologics USA#USA#San_Diego#Cancer_Treatment#Monoclonal_Antibodies#Precision_Biologics
Precision Biologics to Present PB-223 ADC's Cancer-Efficacy at the 6th ACE Drug Discovery Summit#London#United_Kingdom#Precision_Biologics#PB-223_ADC#Philip_Arlen
Precision Biologics to Present PB-223 ADC's Cancer-Efficacy at the 6th ACE Drug Discovery Summit
Precision Biologics, led by CEO Philip M. Arlen, will showcase the effectiveness of its PB-223 ADC targeting cancer at the 6th ACE Drug Discovery Summit in London.
third-news.com
February 13, 2026 at 2:29 PM
Precision Biologics to Present PB-223 ADC's Cancer-Efficacy at the 6th ACE Drug Discovery Summit#London#United_Kingdom#Precision_Biologics#PB-223_ADC#Philip_Arlen
Unlocking the Potential of PB-vcMMAE-5: A Tumor-Specific ADC for Human Cancers#USA#ADC#National_Harbor#Precision_Biologics#PB-vcMMAE-5
Unlocking the Potential of PB-vcMMAE-5: A Tumor-Specific ADC for Human Cancers
Precision Biologics is set to present groundbreaking efficacy data for PB-vcMMAE-5, a novel ADC targeting human cancers, at SITC 2025.
third-news.com
November 5, 2025 at 9:18 PM
Unlocking the Potential of PB-vcMMAE-5: A Tumor-Specific ADC for Human Cancers#USA#ADC#National_Harbor#Precision_Biologics#PB-vcMMAE-5
Precision Biologics to Showcase Promising New ADC for Ovarian Cancer at AACR Conference#USA#Denver#ADC#Ovarian_Cancer#Precision_Biologics
Precision Biologics to Showcase Promising New ADC for Ovarian Cancer at AACR Conference
Precision Biologics will present data on a novel antibody-drug conjugate targeting ovarian cancer at the AACR conference, highlighting its efficacy and potential.
third-news.com
September 19, 2025 at 1:24 PM
Precision Biologics to Showcase Promising New ADC for Ovarian Cancer at AACR Conference#USA#Denver#ADC#Ovarian_Cancer#Precision_Biologics
Precision Biologics Unveils Promising Data for PB-223 ADC at AACR 2025#USA#Chicago#ADC#Precision_Biologics#PB-223
Precision Biologics Unveils Promising Data for PB-223 ADC at AACR 2025
At the AACR Annual Meeting 2025, Precision Biologics will showcase exciting developments surrounding the PB-223 antibody-drug conjugate, showcasing its advancements in cancer therapy.
third-news.com
April 25, 2025 at 1:33 PM
Precision Biologics Unveils Promising Data for PB-223 ADC at AACR 2025#USA#Chicago#ADC#Precision_Biologics#PB-223